- Federal health officials announced that people in the United States vaccinated with Pfizer-BioNTech or Moderna-NIAID may be able to get booster doses as early as this month.
- The news comes as the Delta variant has led to a major surge in COVID-19 cases.
- Health officials said that they expect people who received the one-dose Johnson & Johnson vaccine will need an additional dose, but they’re waiting for results from the company’s two-dose clinical trial.
People in the United States who are fully vaccinated with an mRNA COVID-19 vaccine may soon be eligible for a booster dose 8 months after their second dose, pending approval from the Food and Drug Administration (FDA).
“The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the delta variant, we are starting to see evidence of reduced protection against mild and moderate disease,” said health experts in a joint statement published last month.
The statement was signed by CDC Director Dr. Rochelle Walensky, acting FDA Commissioner Dr. Janet Woodcock, White House chief medical adviser Dr. Anthony Fauci, and other U.S. health leaders.
Booster doses will be available as early as the week of Sept. 20, pending approval by the FDA.
While health officials said that they expect people who received the one-dose Johnson & Johnson vaccine to need an additional dose, they’re waiting for the company’s two-dose clinical trial results.
The Biden administration’s new policy hinges on an independent review of the safety and efficacy of boosters by the FDA and the vaccine advisory committee of the Centers for Disease Control and Prevention (CDC).
However, top federal health officials indicated that the FDA and CDC may need more time to gather the data that will be used to determine whether to recommend boosters for Americans, reported The New York Times on Sept. 3.
Pfizer and BioNTech have submitted data to the FDA to support a booster dose of their vaccine. But the FDA needs additional booster data from Moderna and Johnson & Johnson.
The FDA is also waiting for raw data from Israel on a possible waning effectiveness of the Pfizer-BioNTech vaccine against severe disease and hospitalization as well as the benefits of a booster dose.
On Sept. 17, the FDA’s independent vaccine advisory committee will meet to review data on the Pfizer-BioNTech booster dose.
Details of the plan were released during a White House COVID-19 press briefing on Aug. 18. But the report on Sept. 3 means that many people may not be able to get a booster shot as early as anticipated.
Right now, the FDA may only have enough data to give recommendations about booster shots for people who’ve had the Pfizer-BioNTech COVID-19 vaccine.
When the booster shots are available to everyone, higher-risk populations will be first in line for a booster. This includes residents of long-term-care facilities, healthcare workers, and other frontline workers.
After that, boosters would be made available in a similar way to the initial rollout, with older people likely vaccinated sooner.
Certain immunocompromised people are already eligible for a third dose now that the FDA
This is not considered a “booster” for this group but an “additional dose,” because many people with weakened immune systems don’t generate a robust immune response from the standard regimen.
Dr. Richard Greenberg, an infectious disease physician at the University of Kentucky, said that there hasn’t been enough peer-reviewed data to support a wide rollout of boosters to people in the United States.
He’s the lead investigator for the Kentucky site of a clinical trial to assess varying doses of a Johnson & Johnson booster shot. Studies like this will provide data for making decisions about when boosters are needed.
Last month, Pfizer and BioNTech announced that they submitted early stage clinical trial data to the FDA looking at the benefits of a booster for their vaccine.
The study found that an additional dose generated “significantly higher neutralizing antibodies” against the coronavirus’s original strain and the Beta and Delta variants, reports CNBC.
The study doesn’t show whether people need a higher level of antibodies to fend off severe COVID-19 or if the level they have 8 months or more after full vaccination is enough.
This study “shows an antibody boost with an additional dose, but I didn’t see data to say that it correlates to anything clinical,” said Greenberg.
Some of the Biden administration’s concerns stem from recent Israel government data showing a decline in the protection offered by the Pfizer-BioNTech vaccine, reported The New York Times.
The data suggests a continued decrease in the vaccine’s effectiveness against mild or symptomatic infection overall and severe disease among older adults.
In people 65 years old or older who received their second dose in January, vaccine effectiveness against severe COVID-19 had dropped to 55 percent, according to the Israel data.
However, the Times reported that some experts pointed out that the data has a wide margin of error. Others said more information is needed — including from the United States — to know how well the vaccines work.
Earlier data from the Israeli government in July suggested a less severe drop, with the vaccine still 88 percent effective against hospitalization and 91 percent effective against severe illness.
But this data showed that the vaccine was only 39 percent effective against infection and symptomatic illness.
This contrasts with a U.K. study published in July in The New England Journal of Medicine, which found that a two-dose regimen of the Pfizer-BioNTech vaccine was 88 percent effective against symptomatic infection caused by Delta.
Some U.S. data suggests that the mRNA vaccines continue to protect against severe COVID-19, even with Delta circulating.
One study released Aug. 18 by the CDC found no decline in the vaccines’ effectiveness against COVID-19 hospitalization over 24 weeks.
Another CDC study found that among nursing home residents, vaccine effectiveness dropped from 75 percent in March-May of 2021 to 53 percent in June-July.
No data is available yet on vaccine effectiveness against severe disease for this older population.
In the United States, there are hints at a rise in breakthrough infections in fully vaccinated people in certain states.
It’s not clear whether this trend applies to all states, or whether it’s due to a waning of immunity in the months after vaccination or the higher transmissibility of the Delta variant.
The vaccines, though, were never expected to block all infections. Instead, they were designed to reduce severe illness.
“We don’t want people getting sick and being put in the hospital,” said Greenberg. “That’s what the vaccines are there for — to protect people from severe illness, from dying, and from terrible morbidity.”
The vaccines are still effective for this, even against the Delta variant.
The number of breakthrough cases that have led to hospitalization or death is small. As of Aug. 30, just over 12,908 of these have been
In addition, the vast majority of severe COVID-19 cases and deaths in the United States are among the unvaccinated or partially vaccinated.
The single-dose Johnson & Johnson vaccine has also proven effective against severe illness, including that caused by Delta.
In a recent press release, South African researchers reported that although there were many breakthrough infections, the vaccine was 65 to 66 percent effective against hospitalization due to COVID-19.
The protection against death was even higher — 91 to 95 percent.
However, this study wasn’t designed to see whether people vaccinated earlier in the year had the same protection as people who received their doses more recently.
Some experts say that given the limited data on the need for boosters right now, the United States would be better off vaccinating the unvaccinated.
These people are more likely to end up in the hospital or die from COVID-19. And even if they aren’t at high risk personally, they can easily spread the virus to someone who is.
A little less than 30 percent of eligible Americans haven’t received even one dose, CDC data shows. On top of this, children under 12 years aren’t yet eligible for the vaccines.
Increasing vaccination rates in a community also reduces the risk of infection for everyone.
“Get a booster if you have a very compromised immune system, are a transplant patient, or are very elderly,” Ellie Murray, ScD, an epidemiologist at Boston University School of Public Health, wrote this week on Twitter.
“Otherwise, you reduce your risk way more by convincing your neighbors to get their first & second doses [of an mRNA vaccine] or a single-dose J&J.”
Revaccinating the vaccinated also raises issues of global equity.
In high-income countries, 51 percent of people have received at least one dose, while the rate is only 1 percent in low-income countries, reported Kaiser Family Foundation.
Earlier this month, the World Health Organization (WHO) called on wealthy countries to stop distributing booster doses to give the world a chance to vaccinate at least 10 percent of the population in all countries by the end of September.
“I’m a little worried that there are so many people in the world who need vaccines,” said Greenberg. “Do we have enough [capacity] to jump to this new strategy without taking into account what’s happening around us?”